ETR:BIO Biotest Aktiengesellschaft (BIO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Biotest Aktiengesellschaft Stock (ETR:BIO) 30 days 90 days 365 days Advanced Chart Remove Ads Get BIO alerts:Sign Up Key Stats Today's Range N/A50-Day Range€40.80▼€41.8052-Week Range N/AVolume350 shsAverage Volume1,927 shsMarket Capitalization$807.43 millionP/E Ratio9.83Dividend Yield0.10%Price TargetN/AConsensus RatingN/A Company OverviewBiotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols, S.A.Read More… Remove Ads Receive BIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biotest Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Email Address BIO Stock News HeadlinesEQS-Adhoc: Biotest AG: CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future.March 6, 2025 | markets.businessinsider.comAktien»Nachrichten»BIOTEST AKTIE»EQS-Adhoc: Biotest AG veröffentlicht vorläufige Geschäftszahlen 2024 - Prognosen 2024 teilweise übertroffenFebruary 27, 2025 | finanznachrichten.deDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.March 29, 2025 | Altimetry (Ad)Biotest Aktiengesellschaft (BIO.DE)February 8, 2025 | finance.yahoo.comEQS-Adhoc: Biotest AG: Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchangedNovember 15, 2024 | markets.businessinsider.comBiotest Aktiengesellschaft (BIESF)August 30, 2024 | au.finance.yahoo.comBiotest Aktiengesellschaft (BIO3.F)August 13, 2024 | nz.finance.yahoo.comBiotest Aktiengesellschaft (BIO3.SW)August 4, 2024 | ca.finance.yahoo.comSee More Headlines BIO Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Biotest Aktiengesellschaft own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biotest Aktiengesellschaft investors own include GSK (GSK), Invitae (NVTA), Adaptive Biotechnologies (ADPT), ADMA Biologics (ADMA), Analog Devices (ADI), Adaptimmune Therapeutics (ADAP) and Axcelis Technologies (ACLS). Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryMeasuring And Control Equipment Current SymbolETR:BIO CIKN/A Webwww.biotest.com Phone+49-6103-8010FaxN/AEmployees8,200Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)€4.15 Trailing P/E Ratio9.83 Forward P/E RatioN/A P/E GrowthN/ANet Income$164.40 million Net Margins9.69% Pretax MarginN/A Return on Equity13.11% Return on Assets8.47% Debt Debt-to-Equity RatioN/A Current Ratio2.54 Quick Ratio1.66 Sales & Book Value Annual Sales$781.30 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow31.04 Book Value€14.18 per share Price / BookN/AMiscellaneous Outstanding Shares19,790,000Free FloatN/AMarket Cap$807.43 million OptionableNot Optionable Beta0.24 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (ETR:BIO) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotest Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share Biotest Aktiengesellschaft With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.